PD-L1 and CTLA-4 have been shown to be targeted for a variety of tumor immunotherapy (Chae et al., 2018; Ott, Hodi & Robert, 2013), In HCC, Phase I clinical trials have shown that PD-L1 and CTLA-4 blockers have achieved good clinical results (Kudo, 2017). The gene discussed is CTLA4; the disease is neoplasm.